Key clinical point: During a median follow-up of 13 months, the rate of progression was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide, and patients in the enzalutamide group had more favorable profiles for radiological progression-free survival and overall survival.
Major finding: The rate of metastatic prostate cancer at diagnosis was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide ( P = 0.016); enzalutamide patients had increased radiological progression-free survival and overall survival.
Study details: The data come from a retrospective study of 250 men diagnosed with metastatic castration-resistant prostate cancer who were treated with either abiraterone acetate or enzalutamide.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Demirci A et al. Sci Rep. 2021 Jul 8. doi: 10.1038/s41598-021-93659-x.